8 May 2018 07:00
4D pharma plc
(the "Company" or "4D")
Clinical Update - Blautix IND
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, has today announced that the Company has submitted, and the U.S. Food and Drug Administration (FDA) has cleared, an Investigational New Drug Application for Blautix, the Company's live biotherapeutic for the treatment of Irritable Bowel Syndrome (IBS). Enrolment in the Phase 2 study is expected to commence in the second half of 2018.
The double-blind, placebo-controlled multicentre Phase 2 study will evaluate the efficacy and safety of Blautix in patients with IBS with constipation (IBS-C) and IBS with diarrhoea (IBS-D). 4D has consulted with the FDA on the design of the study. Up to 500 patients will receive either Blautix or placebo daily for 8 weeks. The primary endpoint will be the Overall Response rate, defined as the proportion of patients reporting an improvement in their weekly cohort-specific symptoms (abdominal pain and stool frequency or consistency) for at least 4 out of 8 weeks. A range of secondary efficacy endpoints will also be assessed, as well as the effects of Blautix on the gut microbiome.
Dr. Alex Stevenson, 4D's Chief Scientific Officer, commented: "We are delighted to advance Blautix into this important proof-of-concept study, which brings us another step closer to bringing a novel treatment regime to patients. Despite affecting up to 15% of the population, and a market forecast to be worth more than $2.5 billion by 2024*, IBS is poorly addressed with current therapies, which only target the symptoms of the disease rather than tackling the underlying causes. By targeting the microbiome, Blautix has the potential to make a real difference for patients and could represent a new era in the treatment of IBS."
*Source: EvaluatePharma
For further information please contact:
4D | + 44 (0)113 895 0130 |
Duncan Peyton, Chief Executive Officer
| |
Zeus Capital Limited - Nomad and Joint Broker | |
Dan Bate / Jordan Warburton | +44 (0) 161 831 1512 |
Hugh Kingsmill Moore
| +44 (0) 203 829 5000 |
Bryan Garnier & Co. Limited - Joint Broker | +44 (0)20 7332 2500 |
Dominic Wilson Phil Walker |
About 4D
Founded in February 2014, 4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform that rationally identifies novel bacteria that have a precise and evolved therapeutic effect. All of 4D's live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D has completed a phase I study in Irritable Bowel Syndrome and has completed dosing in a phase I study in Paediatric Crohn's Disease. It currently has a pipeline of 13 pre-clinical programmes, covering disease areas such as cancer, poorly controlled asthma, autoimmune and CNS disease, and plans to commence four additional clinical studies in 2018.
About IBS
IBS is a functional bowel disorder characterised by discomfort, pain and changes in bowel habits. Symptoms can be mild, moderate or severe. Mild symptoms, which occur infrequently, can sometimes interfere with normal daily functioning. Moderate symptoms are more intense, occur more frequently, and often interfere with daily functioning. Severe symptoms chronically interfere with daily functioning. It is estimated that 10-15% of the population have IBS, with only 30-35% of subjects seeking medical attention, the majority of which have persistent symptoms. There are currently few approved treatment options, all of which focus on the modulation of symptoms.
About Blautix
Blautix is a single-strain live biotherapeutic candidate in development for the treatment of IBS-C and IBS-D. The organism was originally isolated from a healthy individual and has a distinctive metabolism which utilises intestinal hydrogen as an energy source, reduces levels of hydrogen sulphide, and increases microbiota diversity and stability. Unlike existing therapies which only seek to address IBS symptoms, by targeting the microbiome Blautix has the potential to act directly on the underlying pathophysiology of disease to treat all IBS patients irrespective of traditional sub-types.